



Natco Pharma Limited
Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

October 31, 2025

Corporate Relationship Department
BSE Ltd.
Mumbai 400 001

Manager – Listing
National Stock Exchange of India Ltd
Mumbai 400 051

Scrip Code: **524816**

Scrip Code: **NATCOPHARM**

Dear Sir/Madam,

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

With reference to the above cited subject, please find enclosed herewith the Press Release under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This is for your information.

Thanking you,

Yours faithfully
For NATCO Pharma Limited

Ch. Venkat Ramesh
Company Secretary &
Compliance Officer

NATCO Pharma Ltd

Natco House
Road No.2, Banjara Hills
Hyderabad-500 034, India

NATCO announces launch of its Everolimus tablets, 1 mg, (generic of Zortress®)

Hyderabad, India, October 31st, 2025: NATCO Pharma Limited (BSE: 524816 and NSE: NATCOPHARM) ("NATCO") announces launch of Everolimus tablets 1mg, a generic version of Zortress® by Novartis, under the therapeutic class of immunosuppressant. NATCO's marketing partner for the ANDA, Breckenridge Pharmaceutical, Inc., the U.S. subsidiary of Towa International, plans to launch the product immediately in the U.S. market.

Everolimus is an mTOR inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in adult patients in kidney and liver transplantation.

Breckenridge previously launched its Everolimus Tablets in 0.25mg, 0.5mg, and 0.75mg strengths, with blisters launched in July 2021 and bottles launched in June 2023.

***Safe Harbor Statement**

Please visit www.breckenridgepharma.com for full prescribing information including warnings, precautions, and adverse reactions.

All brand names and trademarks are the property of their respective owners

About NATCO Pharma Limited

NATCO Pharma Limited, (NSE:NATCOPHARM, BSE: 524816, Reuters: NATP.NS, Bloomberg: NTCPH,) headquartered at Hyderabad, India, develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharmaceutical ingredients and crop protection products. The Company is a R&D oriented, and a science driven, leading Oncology player in the targeted therapies of domestic market and focuses on limited competition molecule in the US. The Company has 9 manufacturing sites and 2 R&D facilities in India. The Company's manufacturing facilities are approved by several leading regulatory authorities like US FDA, Brazil ANVISA, Health Canada, WHO and others catering to 50+ global markets. For more information, please visit us at www.natcopharma.com.

For further information or queries please contact:

Rajeev Menon – Manager, Investor Relations
Email: ir@natcopharma.co.in

Rajesh Chebiyam – EVP, Crop Health Sciences
Email: investors@natcopharma.co.in

Tel: 040-23547532 / Ext – 323

Follow us on:

X (formerly Twitter): https://twitter.com/pharma_natco

LinkedIn: <https://www.linkedin.com/company/natcopharma>